课题基金 / 基金详情

DEVELOPMENT OF VACCINIA VIRUS AS AN EXPRESSION VECTOR

DEVELOPMENT OF VACCINIA VIRUS AS AN EXPRESSION VECTOR
痘苗病毒作为表达载体的开发
批准号:
6098903
负责人:
BERNARD MOSS
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

BERNARD MOSS的其他基金

相似基金

相关文献

中文摘要
翻译
基因表达的细胞质部位及其在基因工程中的应用 病毒编码的酶是痘苗病毒的显著特征。 和其他有助于它们一致能力的痘病毒载体 表达来自各种原核、真核生物的基因 和病毒源。这一功能,加上它们能够稳定地 整合和打包大量额外的DNA,并广泛 宿主范围,说明它们作为研究工具的一般用途 哺乳动物细胞中重组蛋白的合成。重组 牛痘病毒也作为活疫苗进行了测试。在.期间 在过去的一年里,我们一直在评估高度衰减的改装 痘苗病毒安卡拉株在实验室和AS中作为安全媒介 传染病候选疫苗的载体和 癌症。
英文摘要
The cytoplasmic site of gene expression and use of virally encoded enzymes are distinguishing features of vaccinia virus and other poxvirus vectors that contribute to their consistent ability to express genes derived from a variety of prokaryotic, eukaryotic and viral sources. This feature, together with their ability to stably integrate and package large amounts of additional DNA, and broad host range, account for their general use as a research tool and for synthesis of recombinant proteins in mammalian cells. Recombinant vaccinia viruses are also being tested as live vaccines. During the past year, we have been evaluating the highly attenuated modified vaccinia virus Ankara strain as a safe vector in the laboratory and as a vector for candidate vaccines against infectious diseases and cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
VIRUS HOST INTERACTIONS
REGULATION OF VACCINIA VIRUS GENE EXPRESSION
Development of Vaccinia Virus as an Expression Vector
Recombinant and Attenuated Vaccines
海外基金